Cangrelor | Chiesi U.S.A | ||
50 mg/Vial; Powder, Intravenous |
Less Than $1000 mn
|
||
Less Than 5
|
Less Than 5
|
||
Less Than 5
|
Less Than 5
|
||
None | None | ||
KENGREAL is indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor | |||
Yes
|
Kengreal | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 |
---|---|---|---|---|---|---|---|---|
***** ****** | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
***-**** | ********* | ******* | ********* | ******* | ******* | ********* | ******* | ******* |
***** ****** | **** *** | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
---|---|---|---|---|---|
***** ****** | *** \ ********* | ***** **, **** | ******* | **** | ******* *** **** *** *** **** |
***-**** | *** \ ********* | ***** **, **** | ******* | **** | ******* *** **** *** *** **** |
***** ****** | ** \ ** | *** **, **** | ******* | **** | ******* *** **** *** *** **** |